×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ASMB – assembly biosciences, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ASMB
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/25
09:04 am
asmb
Assembly Biosciences, Inc. (NASDAQ: ASMB) is now covered by analysts at Guggenheim. They set a "buy" rating and a $31.00 price target on the stock.
Low
Report
Assembly Biosciences, Inc. (NASDAQ: ASMB) is now covered by analysts at Guggenheim. They set a "buy" rating and a $31.00 price target on the stock.
3/24
11:06 pm
asmb
Assembly Biosciences, Inc. (NASDAQ: ASMB) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
Low
Report
Assembly Biosciences, Inc. (NASDAQ: ASMB) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
3/24
08:09 am
asmb
Assembly Biosciences, Inc. (NASDAQ: ASMB) had its "neutral" rating re-affirmed by analysts at HC Wainwright.
Medium
Report
Assembly Biosciences, Inc. (NASDAQ: ASMB) had its "neutral" rating re-affirmed by analysts at HC Wainwright.
3/20
04:56 pm
asmb
Assembly Biosciences, Inc. (ASMB) Stock [Seeking Alpha]
Low
Report
Assembly Biosciences, Inc. (ASMB) Stock [Seeking Alpha]
3/20
04:05 pm
asmb
Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights
Low
Report
Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights
2/26
08:00 am
asmb
Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus
Medium
Report
Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus
2/20
08:00 am
asmb
Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent Genital Herpes
Low
Report
Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent Genital Herpes
Date
Time
Symbol
Company Name
Action
%Chg
5/8/2024
04:05 pm
ASMB
assembly biosciences, inc.
BEAT
Report
1.2%
assembly biosciences, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/2
06:02 am
asmb
Form EFFECT ASSEMBLY BIOSCIENCES,
Low
Report
Form EFFECT ASSEMBLY BIOSCIENCES,
4/1
04:05 pm
asmb
Form 4 ASSEMBLY BIOSCIENCES, For: Mar 29 Filed by: Bjorkquist Jeanette M
Low
Report
Form 4 ASSEMBLY BIOSCIENCES, For: Mar 29 Filed by: Bjorkquist Jeanette M
4/1
04:05 pm
asmb
Form 4 ASSEMBLY BIOSCIENCES, For: Mar 29 Filed by: White Nicole S
Low
Report
Form 4 ASSEMBLY BIOSCIENCES, For: Mar 29 Filed by: White Nicole S
4/1
04:05 pm
asmb
Form 4 ASSEMBLY BIOSCIENCES, For: Mar 29 Filed by: Okazaki Jason A
Low
Report
Form 4 ASSEMBLY BIOSCIENCES, For: Mar 29 Filed by: Okazaki Jason A
4/1
04:05 pm
asmb
Form 4 ASSEMBLY BIOSCIENCES, For: Mar 29 Filed by: Delaney William E IV
Low
Report
Form 4 ASSEMBLY BIOSCIENCES, For: Mar 29 Filed by: Delaney William E IV
4/1
04:05 pm
asmb
Form 4 ASSEMBLY BIOSCIENCES, For: Mar 29 Filed by: Gaggar Anuj
Low
Report
Form 4 ASSEMBLY BIOSCIENCES, For: Mar 29 Filed by: Gaggar Anuj
3/20
04:16 pm
asmb
Form 10-K ASSEMBLY BIOSCIENCES, For: Dec 31
Low
Report
Form 10-K ASSEMBLY BIOSCIENCES, For: Dec 31
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
12/12
Assembly Biosciences Announces Pricing of $125 Million Public Offering
41.6%
10/15 Assembly Biosciences Inc (NASDAQ: ASMB) is now covered by analysts at Mizuho. They set a "buy" rating on the stock. 36.7%
8/7 Assembly Biosciences Announces Appointment of John McHutchison, AO, MD, as President and Chief Executive Officer 20.2%
10/16 Here's Why Assembly Biosciences Stock Soared Today [The Motley Fool] 19.3%
9/17 Assembly Biosciences Inc (NASDAQ: ASMB) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $13.00 price target on the stock. 16.2%
4/6 Research by Assembly Biosciences and Academic Collaborators Published in Hepatology Indicates cccDNA Turnover Time May Enable Hepatitis B Cures Following Finite Therapy 12.3%
7/1 Assembly Biosciences Inc (NASDAQ: ASMB) had its "hold" rating re-affirmed by analysts at Chardan Capital. 9.8%
3/13 Assembly Biosciences Inc (NASDAQ: ASMB) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 9.6%
3/26 Form SEC STAFF LETTER ASSEMBLY BIOSCIENCES, 9.2%
6/24 Assembly Biosciences Inc (NASDAQ: ASMB) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $15.00 price target on the stock. 7.4%
10/15 Assembly Biosciences Inc (NASDAQ: ASMB) is now covered by analysts at Mizuho. They set a "buy" rating on the stock. 36.7%
8/7 Assembly Biosciences Announces Appointment of John McHutchison, AO, MD, as President and Chief Executive Officer 20.2%
10/16 Here's Why Assembly Biosciences Stock Soared Today [The Motley Fool] 19.3%
9/17 Assembly Biosciences Inc (NASDAQ: ASMB) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $13.00 price target on the stock. 16.2%
4/6 Research by Assembly Biosciences and Academic Collaborators Published in Hepatology Indicates cccDNA Turnover Time May Enable Hepatitis B Cures Following Finite Therapy 12.3%
7/1 Assembly Biosciences Inc (NASDAQ: ASMB) had its "hold" rating re-affirmed by analysts at Chardan Capital. 9.8%
3/13 Assembly Biosciences Inc (NASDAQ: ASMB) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 9.6%
3/26 Form SEC STAFF LETTER ASSEMBLY BIOSCIENCES, 9.2%
6/24 Assembly Biosciences Inc (NASDAQ: ASMB) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $15.00 price target on the stock. 7.4%
TOP News Decliners
11/11
Data for Assembly Biosciences’ First and Second Generation HBV Core Inhibitors in Development for the Treatment of Chronic Hepatitis B Highlighted in Late-Breaker Poster Session at AASLD 2019
-18.2%
10/17 Assembly Biosciences Inc (NASDAQ: ASMB) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -11.0%
12/12 Assembly Biosciences Inc (NASDAQ: ASMB) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -10.6%
8/9 Form 8-K ASSEMBLY BIOSCIENCES, For: Aug 06 -10.1%
9/24 Assembly Biosciences Inc (NASDAQ: ASMB) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.8%
9/27 Assembly Biosciences Inc (NASDAQ: ASMB) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $13.00 price target on the stock. -7.7%
12/13 Form 424B5 ASSEMBLY BIOSCIENCES, -6.1%
5/10 Form SC 13G/A ASSEMBLY BIOSCIENCES, Filed by: EcoR1 Capital, LLC -4.9%
2/14 Form SC 13G/A ASSEMBLY BIOSCIENCES, Filed by: ARMISTICE CAPITAL, LLC -3.9%
6/21 Assembly Biosciences Announces Presentation at International Association for the Study of the Liver Congress and Update on HBV Program in China -3.6%
10/17 Assembly Biosciences Inc (NASDAQ: ASMB) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -11.0%
12/12 Assembly Biosciences Inc (NASDAQ: ASMB) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -10.6%
8/9 Form 8-K ASSEMBLY BIOSCIENCES, For: Aug 06 -10.1%
9/24 Assembly Biosciences Inc (NASDAQ: ASMB) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.8%
9/27 Assembly Biosciences Inc (NASDAQ: ASMB) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $13.00 price target on the stock. -7.7%
12/13 Form 424B5 ASSEMBLY BIOSCIENCES, -6.1%
5/10 Form SC 13G/A ASSEMBLY BIOSCIENCES, Filed by: EcoR1 Capital, LLC -4.9%
2/14 Form SC 13G/A ASSEMBLY BIOSCIENCES, Filed by: ARMISTICE CAPITAL, LLC -3.9%
6/21 Assembly Biosciences Announces Presentation at International Association for the Study of the Liver Congress and Update on HBV Program in China -3.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: